Skip to main content
. Author manuscript; available in PMC: 2017 Mar 30.
Published in final edited form as: N Engl J Med. 2016 Dec 22;375(25):2504–2505. doi: 10.1056/NEJMc1610047

Figure 1. Abstinence from Illicit Opioids and Intravenous Opioids over 12 Weeks with Interim Buprenorphine.

Figure 1

Panel A shows the effects of interim buprenorphine on abstinence from illicit opioid use over 12 weeks. Data points represent the percentage of participants who submitted urine specimens with negative results for illicit opioids at intake and at assessments every 4 weeks thereafter. Panel B shows the effects of interim buprenorphine on the self-reported frequency of the use of illicit opioids, and Panel C shows the effects of interim buprenorphine on the use of intravenous opioids. The y axis for intravenous opioid use is presented on a smaller scale to allow for more detailed inspection of the data. Asterisks represent observations at assessments at 4, 8, and 12 weeks that were significantly different between groups (P<0.001). T bars represent standard errors.